

## Data Sharing Statement

<b>Article Info</b>	<a href="http://dx.doi.org/10.21037/atm-20-8252">http://dx.doi.org/10.21037/atm-20-8252</a>	
<b>Item</b>	<b>Question</b>	<b>Authors' Response (place "-" if not applicable)</b>
1	Would you like to share data collected for your study to others?	Yes
2	If not, would you like to share the reason for your decision?	-
3	What data in particular will be shared?	Results and supplemental appendix will be shared.
4	Any other documents will be shared? Such as study protocol, statistical analysis plan, informed consent form, clinical study report, analytic code.	Study protocol, statistical analysis plan, clinical study report will also be shared if requested.
5	When will data availability begin?	After 1 year.
6	When will data availability end?	After 5 years, because the first-line treatment for HR-positive HER2-negative MBC is changing.
7	To whom will you share the data?	Medical oncologists and breast clinicians who are interested in HR-positive HER2-negative MBC.
8	For what type of analysis or purpose?	For a wider range of investigative research.
9	How or where can the data/documents be obtained?	Emails could be sent to the address below to obtain the shared data: <a href="mailto:yyang123666@163.com">yyang123666@163.com</a> .
10	Any other restrictions?	We may balance the potential benefits and risks for each request and then provide the data that could be shared.